GAMMA Investing’s Iovance Biotherapeutics IOVA Stock Holding History

GAMMA Investing’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$133K	Buy	8,987 +3,565	+66%	+$25.5K	﹤0.01%	1648
2026 Q2	$22.6K	Buy	5,422 +9	+0.2%	+$34	﹤0.01%	2777
2026 Q1	$19K	Buy	5,413 +2,600	+92%	+$8.32K	﹤0.01%	2740
2025 Q4	$7.68K	Buy	+2,813	New	+$6.51K	﹤0.01%	3103
2025 Q2	–	Sell	-1,990	Closed	-$6.63K	–	3835
2025 Q1	$6.63K	Buy	1,990 +804	+68%	+$4.15K	﹤0.01%	2948
2024 Q4	$8.78K	Buy	1,186 +188	+19%	+$1.74K	﹤0.01%	2677
2024 Q3	$9.37K	Sell	998 -1,729	-63%	-$16.4K	﹤0.01%	2491
2024 Q2	$21.9K	Buy	2,727 +1,938	+246%	+$20.8K	﹤0.01%	1793
2024 Q1	$11.7K	Buy	789 +224	+40%	+$2.61K	﹤0.01%	1977
2023 Q4	$4.37K	Buy	+565	New	+$2.96K	﹤0.01%	2297

Other funds holding IOVA

MCP

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

SMAM

Sugar Maple Asset Management Sister Bay, Wisconsin $175M AUM 16.33% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

CWM

Centurion Wealth Management Mclean, Virginia $415M AUM 17.23% 1-Year Est. Return

HCG

Haven Capital Group Westlake Village, California $131M AUM 23.95% 1-Year Est. Return

AWM

Able Wealth Management Toms River, New Jersey $455M AUM 13.63% 1-Year Est. Return

NAM

NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's IOVA Position: Q3 2026 in Review

GAMMA Investing increased its Iovance Biotherapeutics (IOVA) stake by 66% in Q3 2026, buying an estimated $25.5K and bringing the position to 8,987 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #1648.

GAMMA Investing first reported a position in IOVA in Q4 2023 and has held it in 10 quarters since. 13 funds tracked by Wall St. Rank hold IOVA as of Q3 2026.

GAMMA Investing held 8,987 shares of Iovance Biotherapeutics worth $133K as of Q3 2026.
GAMMA Investing bought 3,565 Iovance Biotherapeutics shares in Q3 2026, an estimated $25.5K.
Iovance Biotherapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #1648 holding.
GAMMA Investing first reported a position in Iovance Biotherapeutics in Q4 2023 and has held it in 10 quarters since.
13 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.